8-K: Crescent Biopharma Completes Merger with GlycoMimetics, Secures $200 Million Financing to Advance Oncology Pipeline

Crescent Biopharma, Inc. has successfully completed its merger with GlycoMimetics, Inc. and a private financing round of $200 million, positioning the combined entity to accelerate its oncology pipeline, including lead bispecific antibody CR-001 and novel ADCs.

Summary

• Crescent Biopharma, Inc. (formerly GlycoMimetics, Inc.) has completed its previously announced merger with private Crescent Biopharma, Inc. (referred to as Pre-Merger Crescent).
• Immediately prior to the merger, Pre-Merger Crescent closed a private financing round, raising approximately $200 million in gross proceeds, including $37.5 million from previously issued convertible notes and accrued interest.
• The combined company will operate under the name Crescent Biopharma, Inc. and its shares commenced trading on the Nasdaq Capital Market under the ticker symbol CBIO on June 16, 2025.
• A 1-for-100 reverse stock split of GlycoMimetics common stock was effected immediately prior to the merger.
• Each outstanding share of Pre-Merger Crescent common stock was converted into 0.1445 shares of the combined company's common stock.
• Post-merger, Pre-Merger Crescent securityholders (including financing investors) own approximately 97.3% of the combined company's capital stock on a fully diluted basis, while former GlycoMimetics securityholders own approximately 2.7%.
• The combined company has approximately 19.5 million shares of common stock and common stock equivalents outstanding, including shares underlying pre-funded warrants and Series A convertible preferred stock.
• The financing, combined with existing cash, is expected to fund the company's operations through 2027, supporting multiple anticipated pipeline milestones.
• The lead program, CR-001, a PD-1 x VEGF bispecific antibody, is on track for an Investigational New Drug (IND) application submission in Q4 2025, with proof-of-concept clinical data from a Phase 1 trial expected in H2 2026.
• The company is also advancing novel antibody-drug conjugates (ADCs), CR-002 and CR-003, with an IND submission for CR-002 anticipated in mid-2026.
• The company incurred a net loss of $15.1 million for the three months ended March 31, 2025, and had an accumulated deficit of $33.0 million as of that date.
• Cash and cash equivalents were $22.4 million as of March 31, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful completion of a strategic merger, a substantial capital raise that provides a multi-year runway, and clear advancement of a promising oncology pipeline with defined milestones. The new management team and strategic focus further bolster confidence, despite the inherent risks of early-stage biopharma development and historical losses.

Positives

• Successful completion of a significant merger and a $200 million private financing round provides substantial capital to fund operations through 2027.
• The company has a clear strategic focus on developing novel oncology therapeutics, leveraging a bispecific antibody (CR-001) and antibody-drug conjugates (CR-002, CR-003).
• CR-001, the lead program, is a PD-1 x VEGF bispecific antibody designed to replicate a clinically validated approach, with an IND submission planned for Q4 2025 and proof-of-concept data expected in H2 2026.
• The new management team is experienced, with key appointments including Joshua Brumm as CEO and Peter Harwin as Board Chair, bringing expertise in life sciences investment and biotechnology.
• The company has established key agreements with third-party manufacturers and research organizations (WuXi Biologics, Charles River Laboratories) to support its development pipeline.

Negatives

• The company has incurred significant operating losses since inception, with a net loss of $15.1 million for the three months ended March 31, 2025, and an accumulated deficit of $33.0 million.
• The company has not generated any revenue from product sales to date and does not expect to do so for several years, if ever.
• Future funding requirements are substantial, and there is no assurance that additional funds will be available on acceptable terms or at all, which could lead to delays or termination of development programs.
• The company's approach to drug discovery and development is unproven, and there is no guarantee that clinical trials will yield similar or comparable results to referenced third-party studies (e.g., ivonescimab's HARMONi-2 trial).

Risks

• Uncertainty in the global economy, including inflation, fluctuating interest rates, tariffs, and geopolitical factors, could adversely impact the company's business.
• The ability to successfully complete preclinical and clinical trials, obtain regulatory approval for product candidates, and commercialize products is uncertain.
• Dependence on key personnel and the ability to attract and retain qualified employees is critical.
• Reliance on third-party organizations (vendors, CMOs, CROs) for research, development, and manufacturing exposes the company to supply interruptions and performance risks.
• Protection of proprietary technology and intellectual property rights is crucial, and the company may face challenges in maintaining, expanding, enforcing, and defending its IP portfolio.
• The company's product candidates may not be accepted in the marketplace even if approved, or may not be developed or manufactured at an acceptable cost.
• Regulatory actions with respect to the company's product candidates or its competitors' products and product candidates could impact development timelines and commercial viability.
• The company's ability to manufacture its product candidates in conformity with FDA requirements and to scale up manufacturing to commercial scale, if approved, is a risk.
• The expected potential benefits of strategic collaborations with third parties and the company's ability to attract collaborators with development, regulatory, and commercialization expertise are not guaranteed.
• The company may face competitive responses to its merger and product development efforts.
• The company's public securities' potential liquidity and trading performance are subject to market factors.

Future Outlook

Crescent Biopharma aims to become a world-leading oncology company by rapidly advancing new therapies for cancer patients. The company plans to submit an IND application for its lead program, CR-001, in the fourth quarter of 2025, with proof-of-concept clinical data from a Phase 1 trial expected in the second half of 2026. They also anticipate an IND submission for CR-002, a novel ADC, in mid-2026. The strategy involves developing these candidates as single agents and in combination regimens to treat a range of solid tumors, with the goal of delivering improved clinical efficacy and safety.

Management Comments

• Joshua Brumm, chief executive officer of Crescent, stated: "With our seasoned team, promising pipeline, and solid financial foundation supported by leading biotechnology investors, Crescent is well-positioned to lead the next wave of therapeutic innovation for people living with cancer."
• Joshua Brumm also commented: "We anticipate dosing patients in early 2026 in our global Phase 1 trial for CR-001, a PD-1 x VEGF bispecific antibody. Based on the intentional design of CR-001 to replicate a clinically validated approach, we expect the data we generate in patients with solid tumors to be meaningful."
• Joshua Brumm further added: "We are also advancing two novel ADCs, starting with our CR-002 program which we anticipate entering the clinic in the middle of next year. Our hope is to rapidly bring new treatment options for cancer patients that could truly make a difference in their lives."

Industry Context

This announcement signifies a strategic shift and recapitalization within the biopharma sector, focusing on the high-growth oncology market. The development of bispecific antibodies like CR-001, which targets both PD-1 and VEGF, aligns with a growing industry trend towards multi-modal therapies that aim to enhance efficacy and overcome resistance mechanisms in cancer. The reference to ivonescimab's superior efficacy against pembrolizumab (Keytruda) highlights the competitive landscape and the potential for next-generation immunotherapies. Furthermore, the advancement of novel antibody-drug conjugates (ADCs) with topoisomerase inhibitor payloads positions Crescent within another rapidly evolving and promising area of oncology, where targeted delivery of cytotoxic agents is sought to improve therapeutic index.

Comparison to Industry Standards

• CR-001 is intentionally designed to replicate the cooperative pharmacology of ivonescimab, a bispecific anti-PD-1/anti-VEGF antibody developed by Akeso Biopharma and Summit Therapeutics Inc. This comparison is significant as ivonescimab demonstrated superior progression-free survival in a Phase 3 clinical trial (HARMONi-2) against pembrolizumab (Merck's Keytruda) in non-small cell lung cancer.
• The company aims for CR-001 to deliver improved clinical efficacy and safety over traditional PD-1 inhibitors like pembrolizumab and Opdivo, which are current market leaders in numerous cancer indications.
• The development of CR-002 and CR-003 as novel antibody-drug conjugates (ADCs) with topoisomerase inhibitor payloads positions Crescent in a competitive field with other companies developing next-generation ADCs, which are designed for targeted drug delivery to minimize systemic toxicity and improve therapeutic outcomes.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings or claims as of March 31, 2025.

Related Party Transactions

• Fairmount, Paragon, and Parascent are identified as related parties.
• Fairmount, through an affiliate fund, purchased 20,000,000 shares of Series Seed Preferred Stock for $4.0 million in September 2024.
• Fairmount, through an affiliate fund, holds a Convertible Note with an initial principal amount of $15.0 million (part of the $37.5 million total convertible notes issued in October 2024).
• The company issued 136,612 Restricted Stock Awards (RSAs) to a consultant who is an employee of Fairmount.
• The company issued 1,366,120 RSAs and options to purchase 5,286,600 shares of common stock to its interim Chief Executive Officer (a Fairmount employee), who paid $0.2 million for 1,024,590 of these RSAs.
• The company incurred $8.3 million in expenses with Paragon for services under the Paragon Option Agreements during the three months ended March 31, 2025, recognized as research and development ($8.0 million) and general and administrative ($0.3 million) expenses.
• As of March 31, 2025, $8.3 million in related party accrued expenses (primarily to Paragon) were included in current liabilities.
• Parascent is entitled to grants of warrants to purchase 1.00% of the company's outstanding capital stock on a fully diluted basis on December 31, 2025, and December 31, 2026, as part of the Paragon Option Agreements.
• Upon exercising options and finalizing license agreements, the company will make non-refundable milestone payments to Paragon: up to $22.0 million for CR-001, up to $46.0 million for CR-002, and up to $46.0 million for CR-003, plus tiered royalty payments in the low-to-mid single-digits on net sales.

Stakeholder Impact

• **Shareholders**: Existing GlycoMimetics shareholders experienced a 1-for-100 reverse stock split and significant dilution, now owning ~2.7% of the combined entity. Pre-Merger Crescent shareholders and new investors now hold ~97.3% of the combined company, benefiting from the substantial capital raise and pipeline focus. The redomestication to the Cayman Islands changes certain shareholder rights.
• **Employees**: The new management team is in place, and new stock incentive and employee stock purchase plans are established to align employee interests with the company's success. Some GlycoMimetics employees received severance and retention payments.
• **Customers/Patients**: The company's focus on advancing novel oncology therapies (CR-001, CR-002, CR-003) aims to bring new treatment options for cancer patients, potentially offering improved efficacy and safety.
• **Suppliers/Creditors**: Existing contractual obligations with third-party vendors (e.g., WuXi Biologics, Charles River Laboratories) are maintained, and the significant capital raise improves the company's financial stability and ability to meet obligations.
• **Regulatory Bodies**: The company is committed to complying with all applicable laws and regulations governing the pharmaceutical and biotechnology industries, including SEC requirements as a public company.

Next Steps

• Submit an Investigational New Drug (IND) application for CR-001 in the fourth quarter of 2025.
• Initiate dosing patients in a global Phase 1 trial for CR-001 in early 2026.
• Report proof-of-concept clinical data from the Phase 1 trial of CR-001 in patients with solid tumors in the second half of 2026.
• Submit an IND application for CR-002 (novel ADC) in mid-2026.
• Continue advancing CR-002 and CR-003 (novel ADCs) as single agents and in combination with CR-001.
• Seek and identify additional research programs and product candidates and initiate discovery-related activities and preclinical studies for those programs.
• Pursue investigational new drug applications or comparable foreign applications for future clinical trials.
• Develop, maintain, and enhance cGMP manufacturing capabilities through third parties or internal facilities.
• Seek, obtain, and maintain regulatory approvals for any product candidates.
• Potentially establish a sales, marketing, and distribution infrastructure for commercialization.
• Maintain, expand, enforce, defend, and protect intellectual property portfolio.
• Further acquire or in-license product candidates or programs, intellectual property, and technologies.
• Establish and maintain any future collaborations.

Key Dates

Recommendation

Keywords

Biopharma, Oncology, Merger, Financing, Bispecific Antibody, Antibody-Drug Conjugate, Clinical Trials, Drug Development, SEC Filing, Nasdaq, CR-001, CR-002, CR-003, PD-1, VEGF, Solid Tumors, Biotechnology, Capital Raise, Reverse Stock Split, Corporate Governance